Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077668530> ?p ?o ?g. }
- W2077668530 endingPage "207" @default.
- W2077668530 startingPage "193" @default.
- W2077668530 abstract "Between January 1983 and November 1987, the Radiation Therapy Oncology Group conducted a prospective, randomized, multi-institutional, dose searching Phase I/II trial to evaluate hyperfractionated radiation therapy in the treatment of supratentorial malignant glioma. Patients with anaplastic astrocytoma, or glioblastoma multiforme, age 18-70 years with a Karnofsky performance status of 40-100 were stratified according to age, Karnofsky performance status, and histology, and were randomized. Initially randomization was to one of three arms: 64.8 Gy, 72.0 Gy, and 76.8 Gy. Fractions of 1.2 Gy were given twice daily, 5 days per week, with intervals of 4 to 8 hr. All patients received bis-chlorethyl nitrosourea (BCNU) 80 mg/m2 on days 3, 4, 5 of radiation therapy and then every 8 weeks for 1 year. After acceptable rates of acute and late effects were found, the randomization was changed to 81.6 Gy and 72.0 Gy with a weighting of 2:1. Out of 466 patients randomized, 435 were analyzed. The distribution of prognostic factors was comparable among the 76.8 Gy arm, 81.6 Gy arm, and the final randomization of the 72 Gy arm. The 64.8 Gy arm and the initial randomization of the 72 Gy arm had somewhat worse prognostic variables. Late radiation toxicity occurred in 1.3-6.8% of the patients, with a modest increase with increasing radiation dose. The best survival occurred in those patients treated with 72 Gy (median survival of 12.8 months overall, and 14 months for the final 72 Gy randomization). The Cox proportional hazards model confirmed the prognostic variables of age, histology and Karnofsky performance status. In addition, the longer interval of 4.5-8 hr was associated with a worse prognosis than the 4-4.4 hr interval (p = 0.0011). The difference in survival between the 81.6 Gy arm and the lower three arms approached significance (p = 0.078) with inferior survival observed in the 81.6 Gy arm. When therapy was evaluated by radiation therapy dose received (60-74.4 Gy compared with 74.5-84.0 Gy), the p value was 0.062 in favor of the lower dose range. Patients with anaplastic astrocytoma treated with 72 Gy by hyperfractionation + BCNU had at least as good a survival as those treated with 60 Gy by conventional fractionation + BCNU on Radiation Therapy Oncology Group protocols 7401 and 7918. This suggests that 72 Gy delivered by 1.2 Gy twice daily is no more toxic than 60 Gy delivered by conventional fractionation." @default.
- W2077668530 created "2016-06-24" @default.
- W2077668530 creator A5002120651 @default.
- W2077668530 creator A5026088869 @default.
- W2077668530 creator A5030653008 @default.
- W2077668530 creator A5036811863 @default.
- W2077668530 creator A5037215924 @default.
- W2077668530 creator A5045982614 @default.
- W2077668530 creator A5047419033 @default.
- W2077668530 creator A5060857674 @default.
- W2077668530 creator A5064031032 @default.
- W2077668530 creator A5079124490 @default.
- W2077668530 creator A5081900423 @default.
- W2077668530 date "1993-01-01" @default.
- W2077668530 modified "2023-10-16" @default.
- W2077668530 title "Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma—Possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: Report of the radiation therapy oncology group protocol 8302" @default.
- W2077668530 cites W1969965083 @default.
- W2077668530 cites W1995197521 @default.
- W2077668530 cites W2012803133 @default.
- W2077668530 cites W2014805107 @default.
- W2077668530 cites W2016871222 @default.
- W2077668530 cites W2016888343 @default.
- W2077668530 cites W2021874670 @default.
- W2077668530 cites W2026336655 @default.
- W2077668530 cites W2029445057 @default.
- W2077668530 cites W2047447875 @default.
- W2077668530 cites W2070068475 @default.
- W2077668530 cites W2072427334 @default.
- W2077668530 cites W2073005838 @default.
- W2077668530 cites W2078305681 @default.
- W2077668530 cites W2113012900 @default.
- W2077668530 cites W2161340139 @default.
- W2077668530 cites W2226077283 @default.
- W2077668530 cites W2413376131 @default.
- W2077668530 cites W4236816762 @default.
- W2077668530 cites W4293241248 @default.
- W2077668530 cites W4297792944 @default.
- W2077668530 doi "https://doi.org/10.1016/0360-3016(93)90340-2" @default.
- W2077668530 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8380567" @default.
- W2077668530 hasPublicationYear "1993" @default.
- W2077668530 type Work @default.
- W2077668530 sameAs 2077668530 @default.
- W2077668530 citedByCount "158" @default.
- W2077668530 countsByYear W20776685302012 @default.
- W2077668530 countsByYear W20776685302013 @default.
- W2077668530 countsByYear W20776685302014 @default.
- W2077668530 countsByYear W20776685302015 @default.
- W2077668530 countsByYear W20776685302016 @default.
- W2077668530 countsByYear W20776685302017 @default.
- W2077668530 countsByYear W20776685302018 @default.
- W2077668530 countsByYear W20776685302019 @default.
- W2077668530 countsByYear W20776685302020 @default.
- W2077668530 countsByYear W20776685302021 @default.
- W2077668530 countsByYear W20776685302022 @default.
- W2077668530 countsByYear W20776685302023 @default.
- W2077668530 crossrefType "journal-article" @default.
- W2077668530 hasAuthorship W2077668530A5002120651 @default.
- W2077668530 hasAuthorship W2077668530A5026088869 @default.
- W2077668530 hasAuthorship W2077668530A5030653008 @default.
- W2077668530 hasAuthorship W2077668530A5036811863 @default.
- W2077668530 hasAuthorship W2077668530A5037215924 @default.
- W2077668530 hasAuthorship W2077668530A5045982614 @default.
- W2077668530 hasAuthorship W2077668530A5047419033 @default.
- W2077668530 hasAuthorship W2077668530A5060857674 @default.
- W2077668530 hasAuthorship W2077668530A5064031032 @default.
- W2077668530 hasAuthorship W2077668530A5079124490 @default.
- W2077668530 hasAuthorship W2077668530A5081900423 @default.
- W2077668530 hasConcept C141071460 @default.
- W2077668530 hasConcept C155806632 @default.
- W2077668530 hasConcept C168563851 @default.
- W2077668530 hasConcept C204243189 @default.
- W2077668530 hasConcept C2776694085 @default.
- W2077668530 hasConcept C2776755627 @default.
- W2077668530 hasConcept C2776946711 @default.
- W2077668530 hasConcept C2778227246 @default.
- W2077668530 hasConcept C2778880634 @default.
- W2077668530 hasConcept C2779083369 @default.
- W2077668530 hasConcept C2779429289 @default.
- W2077668530 hasConcept C2779434656 @default.
- W2077668530 hasConcept C2908786992 @default.
- W2077668530 hasConcept C2989005 @default.
- W2077668530 hasConcept C502942594 @default.
- W2077668530 hasConcept C509974204 @default.
- W2077668530 hasConcept C71924100 @default.
- W2077668530 hasConceptScore W2077668530C141071460 @default.
- W2077668530 hasConceptScore W2077668530C155806632 @default.
- W2077668530 hasConceptScore W2077668530C168563851 @default.
- W2077668530 hasConceptScore W2077668530C204243189 @default.
- W2077668530 hasConceptScore W2077668530C2776694085 @default.
- W2077668530 hasConceptScore W2077668530C2776755627 @default.
- W2077668530 hasConceptScore W2077668530C2776946711 @default.
- W2077668530 hasConceptScore W2077668530C2778227246 @default.
- W2077668530 hasConceptScore W2077668530C2778880634 @default.
- W2077668530 hasConceptScore W2077668530C2779083369 @default.
- W2077668530 hasConceptScore W2077668530C2779429289 @default.
- W2077668530 hasConceptScore W2077668530C2779434656 @default.
- W2077668530 hasConceptScore W2077668530C2908786992 @default.
- W2077668530 hasConceptScore W2077668530C2989005 @default.